Given the promising effects of microglial Hrh4 deletion in early stages of AD, it is critical to further evaluate its potential to reverse cognitive impairments in the advanced stage of AD, which are highly relevance to AD patients. The gene discussed is HRH4; the disease is Cognitive impairment.